GLP-1 Drugs Reshape Restaurant and Food Industries

The rising adoption of GLP-1 receptor agonist medications, initially designed for managing type 2 diabetes, is significantly impacting the restaurant and food industries, presenting both challenges and opportunities for businesses. Approximately one in eight U.S. Adults (12%) are currently taking a GLP-1 drug like Ozempic or Zepbound, according to a November 2025 KFF Health Tracking Poll [KFF], a number expected to climb as oral versions develop into available.

The Impact on Consumer Behavior

GLP-1 drugs operate by slowing digestion, suppressing appetite, and increasing satiety. This leads to noticeable changes in consumer behavior, particularly around food consumption. Users of these medications consume, on average, 21% fewer calories and spend nearly a third less on groceries [CNBC]. Approximately 70% of GLP-1 users report snacking less [CNBC].

Financial Implications for the Food Industry

JPMorgan estimates that the increased apply of GLP-1 medications could reduce annual sales for the food and beverage industry by $30 billion to $55 billion as early as 2030 [CNBC]. This potential decline is prompting restaurants and food manufacturers to adapt their strategies.

Restaurant Industry Responses

Restaurants are responding in several ways, including offering smaller portion sizes, emphasizing protein content, and focusing on healthier options. Clinton Hall, for example, introduced a “Teeny Weeny Mini Meal” featuring smaller versions of its standard offerings [CNBC]. Darden Restaurants, owner of Olive Garden, launched a “Lighter Portions” menu in 2025, offering smaller entrees at a lower price point [CNBC].

Dining habits are similarly shifting. Restaurant visits are declining, with some surveys indicating a potential decrease of up to 45% depending on the type of restaurant and occasion [CNBC]. Breakfast and dinner are experiencing the most significant impact, while lunch remains relatively stable. Alcohol consumption with meals is also decreasing, with approximately 45% of respondents eating and drinking less also reporting reduced alcohol intake [CNBC].

Big Food Adapts

Food companies are also evolving their product offerings. PepsiCo has released protein-packed Doritos and fiber-rich varieties of SunChips and Smartfood popcorn [CNBC]. Nestle launched Virtual Pursuit, a frozen-food brand specifically targeting GLP-1 users, and has updated packaging to prominently highlight its suitability for this demographic [CNBC]. J&J Snack Foods is adding protein to its soft pretzels and introducing smaller portion sizes of its Icee products [CNBC].

Future Outlook

While the long-term effects of GLP-1 medications on the food industry remain uncertain, the trend is expected to continue, with projections estimating that over 30 million Americans could be on a GLP-1 treatment by 2030, up from 10 million in 2026 [CNBC]. The introduction of oral GLP-1 drugs is likely to further accelerate adoption. Companies that proactively adapt to these changing consumer habits by offering healthier, protein-rich, and appropriately sized options are best positioned to succeed in this evolving landscape.